Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Thorax ; 75(7): 606-608, 2020 07.
Article in English | MEDLINE | ID: mdl-32354738

ABSTRACT

In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients at 4 sites in Southeast Africa. We show that tuberculosis Molecular Bacterial Load Assay (TB-MBLA) reduces time-to-TB-bacillary-load-result from days/weeks by culture to hours and detects early patient treatment response. By day 14 of treatment, 5% of patients had cleared bacillary load to zero, rising to 58% by 12th week of treatment. Fall in bacillary load correlated with mycobacterial growth indicator tube culture time-to-positivity (Spearmans r=-0.51, 95% CI (-0.56 to -0.46), p<0.0001). Patients with high pretreatment bacillary burdens (above the cohort bacillary load average of 5.5log10eCFU/ml) were less likely to convert-to-negative by 8th week of treatment than those with a low burden (below cohort bacillary load average), p=0.0005, HR 3.1, 95% CI (1.6 to 5.6) irrespective of treatment regimen. TB-MBLA distinguished the bactericidal effect of regimens revealing the moxifloxacin-20 mg rifampicin regimen produced a shorter time to bacillary clearance compared with standard-of-care regimen, p=0.008, HR 2.9, 95% CI (1.3 to 6.7). Our data show that the TB-MBLA could inform clinical decision making in real-time and expedite drug TB clinical trials.


Subject(s)
Antibiotics, Antitubercular/therapeutic use , Mycobacterium tuberculosis/growth & development , Sputum/microbiology , Tuberculosis, Pulmonary/microbiology , Adult , Bacterial Load , Biomarkers/metabolism , Female , Follow-Up Studies , Humans , Male , Mycobacterium tuberculosis/isolation & purification , Prognosis , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/metabolism
2.
J Antimicrob Chemother ; 74(5): 1223-1232, 2019 05 01.
Article in English | MEDLINE | ID: mdl-30778540

ABSTRACT

OBJECTIVES: ESBL-producing Klebsiella pneumoniae (KPN) pose a major threat to human health globally. We carried out a WGS study to understand the genetic background of ESBL-producing KPN in Malawi and place them in the context of other global isolates. METHODS: We sequenced genomes of 72 invasive and carriage KPN isolates collected from patients admitted to Queen Elizabeth Central Hospital, Blantyre, Malawi. We performed phylogenetic and population structure analyses on these and previously published genomes from Kenya (n = 66) and from outside sub-Saharan Africa (n = 67). We screened for presence of antimicrobial resistance (AMR) genetic determinants and carried out association analyses by genomic sequence cluster, AMR phenotype and time. RESULTS: Malawian isolates fit within the global population structure of KPN, clustering into the major lineages of KpI, KpII and KpIII. KpI isolates from Malawi were more related to those from Kenya, with both collections exhibiting more clonality than isolates from the rest of the world. We identified multiple ESBL genes, including blaCTX-M-15, several blaSHV, blaTEM-63 and blaOXA-10, and other AMR genes, across diverse lineages of the KPN isolates from Malawi. No carbapenem resistance genes were detected; however, we detected IncFII and IncFIB plasmids that were similar to the carbapenem resistance-associated plasmid pNDM-mar. CONCLUSIONS: There are multiple ESBL genes across diverse KPN lineages in Malawi and plasmids in circulation that are capable of carrying carbapenem resistance. Unless appropriate interventions are rapidly put in place, these may lead to a high burden of locally untreatable infection in vulnerable populations.


Subject(s)
Genome, Bacterial , Genomics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/genetics , beta-Lactamases/genetics , Anti-Bacterial Agents/pharmacology , Computational Biology/methods , Drug Resistance, Multiple, Bacterial , Genetic Variation , Genomics/methods , Humans , Klebsiella pneumoniae/isolation & purification , Malawi , Microbial Sensitivity Tests , Phylogeny
4.
J Antimicrob Chemother ; 72(6): 1602-1609, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28333330

ABSTRACT

Objectives: Efforts to treat Escherichia coli infections are increasingly being compromised by the rapid, global spread of antimicrobial resistance (AMR). Whilst AMR in E. coli has been extensively investigated in resource-rich settings, in sub-Saharan Africa molecular patterns of AMR are not well described. In this study, we have begun to explore the population structure and molecular determinants of AMR amongst E. coli isolates from Malawi. Methods: Ninety-four E. coli isolates from patients admitted to Queen's Hospital, Malawi, were whole-genome sequenced. The isolates were selected on the basis of diversity of phenotypic resistance profiles and clinical source of isolation (blood, CSF and rectal swab). Sequence data were analysed using comparative genomics and phylogenetics. Results: Our results revealed the presence of five clades, which were strongly associated with E. coli phylogroups A, B1, B2, D and F. We identified 43 multilocus STs, of which ST131 (14.9%) and ST12 (9.6%) were the most common. We identified 25 AMR genes. The most common ESBL gene was bla CTX-M-15 and it was present in all five phylogroups and 11 STs, and most commonly detected in ST391 (4/4 isolates), ST648 (3/3 isolates) and ST131 [3/14 (21.4%) isolates]. Conclusions: This study has revealed a high diversity of lineages associated with AMR, including ESBL and fluoroquinolone resistance, in Malawi. The data highlight the value of longitudinal bacteraemia surveillance coupled with detailed molecular epidemiology in all settings, including low-income settings, in describing the global epidemiology of ESBL resistance.


Subject(s)
Drug Resistance, Multiple, Bacterial/genetics , Escherichia coli Infections/microbiology , Escherichia coli/drug effects , Escherichia coli/genetics , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , Adolescent , Adult , Child , Child, Preschool , Chloramphenicol/pharmacology , Escherichia coli/isolation & purification , Escherichia coli Infections/epidemiology , Female , Genes, Bacterial , Genetic Variation , Genomics , Humans , Malawi/epidemiology , Male , Microbial Sensitivity Tests , Multilocus Sequence Typing , Phylogeny , Urban Population/statistics & numerical data , Young Adult
5.
Tuberculosis (Edinb) ; 98: 110-5, 2016 05.
Article in English | MEDLINE | ID: mdl-27156626

ABSTRACT

Faster elimination of drug tolerant 'persister' bacteria may shorten treatment of tuberculosis (TB) but no method exists to quantify persisters in clinical samples. We used automated image analysis to assess whether studying growth characteristics of individual Mycobacterium tuberculosis colonies from sputum on solid media during early TB treatment facilitates 'persister' phenotyping. As Time to Detection (TTD) in liquid culture inversely correlates with total bacterial load we also evaluated the relationship between individual colony growth parameters and TTD. Sputum from TB patients in Malawi was prepared for solid and liquid culture after 0, 2 and 4 weeks of treatment. Serial photography of agar plates was used to measure time to appearance (lag time) and radial growth rate for each colony. Mixed-effects modelling was used to analyse changing growth characteristics from serial samples. 20 patients had colony measurements recorded at ≥1 time-point. Overall lag time increased by 6.5 days between baseline and two weeks (p = 0.0001). Total colony count/ml showed typical biphasic elimination, but long lag time colonies (>20days) had slower, monophasic decline. TTD was associated with minimum lag time (time to appearance of first colony1). Slower elimination of long lag time colonies suggests that these may represent a persister subpopulation of bacilli.


Subject(s)
Antitubercular Agents/therapeutic use , Bacterial Load , Image Interpretation, Computer-Assisted , Microscopy , Mycobacterium tuberculosis/drug effects , Sputum/microbiology , Tuberculosis, Pulmonary/drug therapy , Drug Resistance, Bacterial , Humans , Malawi , Mycobacterium tuberculosis/growth & development , Phenotype , Predictive Value of Tests , Time Factors , Treatment Outcome , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...